open access

Vol 69, No 4 (2018)
Original paper
Submitted: 2018-01-04
Accepted: 2018-04-22
Published online: 2018-06-07
Get Citation

Dose titration model and correlative factors analysis in Chinese patients with type-2 diabetes on basal insulin — results from an Observational Registry of Basal Insulin Treatment study

Jing Chen, Ying-Li Chen, Li-Nong Ji, Pu-Hong Zhang, Dong-Shan Zhu, Xian Li, Jia-Chao Ji, Fang Zhao, Heng Zhang
·
Pubmed: 29952407
·
Endokrynol Pol 2018;69(4):395-402.

open access

Vol 69, No 4 (2018)
Original Paper
Submitted: 2018-01-04
Accepted: 2018-04-22
Published online: 2018-06-07

Abstract

Introduction: This study evaluates an insulin dose titration model and factors that impact insulin dose adjustment in Chinese adults with type-2 diabetes, who receive basal insulin in real-world settings.

Material and methods: A total of 19,894 patients from the ORBIT study were included. These patients were divided into four groups, according to the type of insulin dose adjustment: no insulin titration (group A), self-titration (group B), physician-led insulin titration (group C), and combined physician and patient-led insulin titration (group D). Data were collected and compared at baseline and after six months of treatment.

Results: A total of 12,865 patients completed the visits and were included in the analysis. Among these patients, 3187 (24.8%), 1971 (15.3%), 5165 (40.1%), and 2542 (19.8%) patients were included in groups A, B, C, and D, respectively. The multivariate logistic regression analysis revealed that the duration of diabetes, body mass index, microvascular complications, inpatient days, HbA1C level, and self-monitoring of blood glucose (SMBG) were positively correlated with insulin titration in group B, C, and D, compared with group A. The number of inpatient days and outpatient visits were positively correlated with dose adjustment for physician-led titration, while this was negatively correlated for self-titration. Self-titration encouraged by physicians and home blood glucose monitoring were positively correlated with self-titration and the combined physician and patient-led titration.

Conclusions: High HbA1C level, SMBG, long disease duration, microvascular complications, and the encouragement of physicians while initiating insulin use prompt patients to perform dose adjustments in real-world settings.

Abstract

Introduction: This study evaluates an insulin dose titration model and factors that impact insulin dose adjustment in Chinese adults with type-2 diabetes, who receive basal insulin in real-world settings.

Material and methods: A total of 19,894 patients from the ORBIT study were included. These patients were divided into four groups, according to the type of insulin dose adjustment: no insulin titration (group A), self-titration (group B), physician-led insulin titration (group C), and combined physician and patient-led insulin titration (group D). Data were collected and compared at baseline and after six months of treatment.

Results: A total of 12,865 patients completed the visits and were included in the analysis. Among these patients, 3187 (24.8%), 1971 (15.3%), 5165 (40.1%), and 2542 (19.8%) patients were included in groups A, B, C, and D, respectively. The multivariate logistic regression analysis revealed that the duration of diabetes, body mass index, microvascular complications, inpatient days, HbA1C level, and self-monitoring of blood glucose (SMBG) were positively correlated with insulin titration in group B, C, and D, compared with group A. The number of inpatient days and outpatient visits were positively correlated with dose adjustment for physician-led titration, while this was negatively correlated for self-titration. Self-titration encouraged by physicians and home blood glucose monitoring were positively correlated with self-titration and the combined physician and patient-led titration.

Conclusions: High HbA1C level, SMBG, long disease duration, microvascular complications, and the encouragement of physicians while initiating insulin use prompt patients to perform dose adjustments in real-world settings.

Get Citation

Keywords

type 2 diabetes, basal insulin therapy, diabetes education, real-world settings, ORBIT study

About this article
Title

Dose titration model and correlative factors analysis in Chinese patients with type-2 diabetes on basal insulin — results from an Observational Registry of Basal Insulin Treatment study

Journal

Endokrynologia Polska

Issue

Vol 69, No 4 (2018)

Article type

Original paper

Pages

395-402

Published online

2018-06-07

Page views

3466

Article views/downloads

1038

DOI

10.5603/EP.a2018.0037

Pubmed

29952407

Bibliographic record

Endokrynol Pol 2018;69(4):395-402.

Keywords

type 2 diabetes
basal insulin therapy
diabetes education
real-world settings
ORBIT study

Authors

Jing Chen
Ying-Li Chen
Li-Nong Ji
Pu-Hong Zhang
Dong-Shan Zhu
Xian Li
Jia-Chao Ji
Fang Zhao
Heng Zhang

References (20)
  1. Yang W, Lu J, Weng J, et al. China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362(12): 1090–1101.
  2. Holman RR, Paul SK, Bethel MA, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131): 837–853.
  3. Nathan DM, Genuth S, Lachin J, et al. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977–986.
  4. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577–1589.
  5. Ji L, Zhang P, Weng J, et al. Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China--Study Design and Baseline Characteristics. Diabetes Technol Ther. 2015; 17(10): 735–744.
  6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55(6): 1577–1596.
  7. Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013; 36(8): 2271–2279.
  8. Xu Yu. Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310(9): 948–959.
  9. Xiong Z, Yuan Li, Guo X, et al. Rejection of insulin therapy among patients with type 2 diabetes in China: reasons and recommendations. Chin Med J (Engl). 2014; 127(20): 3530–3536.
  10. Peyrot M, Rubin RR, Lauritzen T, et al. International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005; 28(11): 2673–2679.
  11. Ji LN, Lu JM, Guo XH, et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health. 2013; 13: 602.
  12. Ji L, Zhang P, Weng J, et al. Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China--Study Design and Baseline Characteristics. Diabetes Technol Ther. 2015; 17(10): 735–744.
  13. DeFronzo RA, Stonehouse AH, Han J, et al. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010; 27(3): 309–317.
  14. Yin J, Yeung R, Luk A, et al. Gender, diabetes education, and psychosocial factors are associated with persistent poor glycemic control in patients with type 2 diabetes in the Joint Asia Diabetes Evaluation (JADE) program. J Diabetes. 2016; 8(1): 109–119.
  15. Zhu H, Zhu Y, Leung SW. Is self-monitoring of blood glucose effective in improving glycaemic control in type 2 diabetes without insulin treatment: a meta-analysis of randomised controlled trials. BMJ Open. 2016; 6(9): e010524.
  16. Ji L, Su Q, Feng B, et al. Glycemic control and self-monitoring of blood glucose in Chinese patients with type 2 diabetes on insulin: Baseline results from the COMPASS study. Diabetes Res Clin Pract. 2016; 112: 82–87.
  17. McAndrew L, Schneider SH, Burns E, et al. Does patient blood glucose monitoring improve diabetes control? A systematic review of the literature. Diabetes Educ. 2007; 33(6): 991–1011; discussion 1012.
  18. Blonde L, Merilainen M, Karwe V, et al. TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab. 2009; 11(6): 623–631.
  19. Harris SB, Yale JF, Berard L, et al. Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: a randomized noninferiority trial. Diabetes Care. 2014; 37(3): 604–610.
  20. Khunti K, Davies MJ, Kalra S. Self-titration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care. Diabetes Obes Metab. 2013; 15(8): 690–700.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl